From: Antigen epitopes of animal coronaviruses: a mini-review
Coronaviruses (protein) | Sequence | Application | References |
---|---|---|---|
PEDV (S-COE) | Y748SNIGVCK755 | Vaccine: production of neutralizing antibody (used HBcAg as vector) | Gillam and Zhang 2018 |
PEDV (S) | T592SLLASACTIDLFGYP607 | Vaccine: production of neutralizing antibody | Sun et al. 2019 |
FIPV (S) | N621NYLTFNKFCLSLSPVGANC640 | Vaccine: induce Th1 activity | Takano et al. 2014 |
FIPV (M) | V81YGIKMLIMWLLWPIVLALT100 | Vaccine: induce Th1 activity | Takano et al. 2014 |
FIPV (N) | G81QRKELPERWFFYFLGTGPH100 | Vaccine: induce Th1 activity | Satoh et al. 2011 |
IBV (S) | S413RIQTATDP421, 517RNATGSQP525, G45AYAVVNV52, S413RIQTATQP421 | Vaccine: stimulate CD8 + T-cell proliferation and IFN-γ secretion | Tan et al. 2016 |
TGEV (S) | TGEV S-A site (533–705) | Vaccine: increase the Th1 and Th2 cytokine levels | Gebauer et al. 1991 |
MHV (S: S1/S2 junction) | L766TTFEPFTVSIVNDS780 | Vaccine: induces CD4 T-cell response in mice | Khanolkar et al. 2010 |
PEDV (S-COE) | T592SLLASACTIDLFGYP607 | Diagnosis: mABs 4D8F10 and 6F3E3 recognize the COE, and highly conserved | Sun et al. 2019 |
TGEV (S) | T592SLLASACTIDLFGYP607 | Diagnosis: highly conserved | Gebauer et al. 1991 |
MHV (N) | I24LKKTTWADQTERGL38 R357FDSTLPGFETIMKVL372 | Diagnosis (ELISA): more sensitive than the commercial tests | Asano et al. 2011 |
IBV (S) | TGEV (S1: 166–247, S1: 501–515, S2: 8–30) | Diagnosis (ELISA): more sensitive and specific than the commercial tests | Ding et al. 2015 |